Gaudium IVF & Women Health IPO Details
| Detail | Description |
|---|---|
| IPO Date | 20 to 24 Feb, 2026 |
| Listing Date | Fri, Feb 27, 2026 |
| Face Value | ₹ 5 per sharee |
| Issue Price Band | ₹ 75 to ₹ 79 |
| Lot Size | 189 Shares |
| Sale Type | Fresh Capital & OFS |
| Total Issue Size | 2,08,86,200 shares (agg. up to ₹ 165 Cr) |
| Fresh Issue(Ex Market Maker) | 1,13,92,500 shares (agg. up to ₹ 90 Cr) |
| Offer for Sale | 94,93,700 shares of ₹5 (agg. up to ₹ 75 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE and NSE |
| Share Holding Pre Issue | 6,13,94,384 shares |
| Share Holding Post Issue | 7,27,86,884 shares |
About Gaudium IVF & Women Health IPO
Gaudium IVF And Women Health IPO is a book-building IPO of 2.09 crore worth up to ₹165 Cr, which is a combination of a fresh issue of ₹90 Cr and an offer for sale of ₹75 crore. The price band for this IPO is set at ₹75 to ₹79 and the lot size for an application is 189 Shares. The minimum amount of investment required by an individual investor (retail investor) is ₹ 14.931(189 shares). The IPO opens for subscription from 20 to 24 Feb, 2026, on the BSE and NSE platforms with a tentative listing date fixed as Fri, Feb 27, 2026.
Company Background
Gaudium IVF & Women Health Ltd. was established in 2015 by the renowned infertility specialist Dr. Manika Khanna. It is a leading reproductive healthcare service provider in India. The company has a state-of-the-art "hub-and-spoke" system, providing world-class Assisted Reproductive Technology (ART) services through its extensive network of healthcare centers. To make world-class fertility care affordable, it has emerged as a reliable destination for patients from across the globe, having completed over 11,000 IVF cycles so far.
Operations & Product Range
Facility & Production
The infrastructure of Gaudium IVF & Women Health Ltd. consists of 7 major hubs (Centers of Excellence) and 28 spokes spread over various states, such as Delhi NCR, Mumbai and Bangalore. The flagship Janakpuri facility is a 15-bed specialty hospital with state-of-the-art embryology labs. The labs are equipped with the latest technology, such as the INTEGRA Ti™ ICSI system and Samsung ultrasound monitoring, to ensure the highest success rates in the treatment of infertility.
Brand & Market presence
Gaudium IVF & Women Health Ltd. is known to be one of the most trusted fertility brands in India, often ranked #1 in various surveys such as the Times Health Survey. It has a considerable market share in the growing IVF market in India, which is expected to reach $1.8 billion by 2029. The brand is further fortified by its "radiation-free IVF" and strong presence in the medical tourism segment, with patients from over 30 countries.
Revenue Channels
- • Primary revenue from high-value IVF, IUI, and ICSI treatment cycles.
- • Income from advanced screenings, including laparoscopy and ultrasound-guided biopsies.
- • Sales from in-house pharmacies and specialized women’s healthcare consultations.
- • Recurring revenue from long-term storage of eggs, sperm, and embryos (vitrification).
Management & shareholding
Promoter & Shareholding
Gaudium IVF & Women Health Ltd. is mainly promoted by Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna. Before the IPO, the promoters were holding a majority of the equity shares. The latest IPO filing includes a substantial fresh issue of 1.13 crore shares and an Offer for Sale (OFS) by Dr. Manika Khanna, which aims to reduce the promoter holding to enable public participation and support aggressive expansion.
Board Members
The Board Members of Gaudium IVF & Women Health Ltd. are led by Dr. Manika Khanna (CMD) and Dr. Peeyush Khanna as Whole-Time Directors. The Board is aided by a pool of seasoned Independent Directors, such as Rajesh Bhojani (former President of UTI Mutual Fund) and Brajesh Singh Bhadauria, to ensure proper financial management during this phase of transitioning into a publicly listed company.
IPO Objectives
- • Funding in the setup of establishment of new IVF centers
- • Repayment of debt (in part or in full)
- • General corporate purposes
Conclusion
Gaudium IVF & Women Health IPO is an opportunity for investors to invest in a growing company that represents a significant milestone as it marks the first major specialized fertility chain to tap into the Indian public markets. This IPO will help the company in the establishment of new IVF centers and debt reduction by this proceeding that will help them in strengthening their balance sheet.
Gaudium IVF & Women Health IPO Financial Information
Latest Revenue
49.75
₹ Crore
Profit After Tax
12.51
₹ Crore
Net Worth
58.85
₹ Crore
Total Borrowing
22.51
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Reserves & Surplus | Total Borrowing | |||
|---|---|---|---|---|---|---|---|---|---|
| 30 Sep 2025 | 106.62 | 49.75 | 12.51 | 58.85 | 28.16 | 22.51 | |||
| 31 Mar 2025 | 88.51 | 70.96 | 19.13 | 46.30 | 15.60 | 18.93 | |||
| 31 Mar 2024 | 51.01 | 48.15 | 10.32 | 26.99 | 26.00 | 15.72 | |||
| 31 Mar 2023 | 36.63 | 44.26 | 13.53 | 22.73 | 21.74 | 9.78 | |||
| Amount in ₹ Crore | |||||||||
Gaudium IVF & Women Health Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 21.25% |
| ROCE | 21.03% |
| Debt/Equity | 0.38 |
| RoNW | 21.34% |
| PAT Margin | 25.14% |
| EBITDA Margin | 38.29% |
| Price to Book Value | - |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 3.12 | 3.44 |
| P/E (x) | 25.36 | 22.99 |
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Pan-India hub-and-spoke fertility clinic network with growing footprint.
Comprehensive advanced reproductive treatments including IVF, ICSI and IUI services.
Strong revenue and profit growth trend in recent fiscal periods.
Using the advanced INTEGRA Ti labs for ICSI
Download regulatory filings
Gaudium IVF & Women Health IPO Timeline
| IPO Open Date | Fri, Feb 20, 2026 |
| IPO Close Date | Wed, Feb 25, 2026 |
| Tentative Allotment | Thu, Feb 26, 2026 |
| Initiation of Refunds | Tue, Feb 24, 2026 |
| Credit of Shares to Demat | Wed, Feb 25, 2026 |
| Tentative Listing Date | Fri, Feb 27, 2026 |
| Cut-off time for UPI mandate confirmation | - |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 1 | 189 | ₹14,931 |
| Individual investors (Retail) (Max) | 13 | 2,457 | ₹2,457 |
| S-HNI (Min) | 14-15 | 2,646 | ₹2,09,034 |
| S-HNI (Max) | 66-70 | 12,474 | ₹9,85,446 |
| B-HNI (Min) | 71+ | 12,663 | ₹10,00,377 |